公开(公告)号：US20080138404A1

公开(公告)日：2008-06-12

申请号：US11945422

申请日：2007-11-27

Applicant: Edwin WALSH ,  Ann Marie YOUNG ,  Graham JACKSON

Inventor： Edwin WALSH ,  Ann Marie YOUNG ,  Graham JACKSON

IPC: A61K9/22 ,  A61K31/403 ,  A61K9/52

CPC classification number: A61K31/403 ,  A61K9/2031

Abstract: An improved controlled release dosage form for once-daily administration of carvedilol is described. The controlled release dosage form comprises a therapeutically effective amount of carvedilol and/or a pharmaceutically acceptable salt thereof; one or more hydrophilic polymers; one or more pharmaceutically acceptable excipients; and a polyoxyalkylene block copolymer, a solid dispersion of carvedilol and an extrusion material or a combination of a polyoxyalkylene block copolymer, a solid dispersion of carvedilol and an extrusion material.

Abstract translation: 描述了一种每日一次给予卡维地洛的改进的控释剂型。 控释剂型包含治疗有效量的卡维地洛和/或其药学上可接受的盐; 一种或多种亲水聚合物; 一种或多种药学上可接受的赋形剂; 和聚氧化烯嵌段共聚物，卡​​维地洛的固体分散体和挤出材料或聚氧化烯嵌段共聚物，卡​​维地洛的固体分散体和挤出材料的组合。

公开(公告)号：US20090246276A1

公开(公告)日：2009-10-01

申请号：US12360673

申请日：2009-01-27

Applicant: Graham Jackson ,  Edwin Walsh ,  Werner Oberegger ,  Xiaopin Jin

Inventor： Graham Jackson ,  Edwin Walsh ,  Werner Oberegger ,  Xiaopin Jin

IPC: A61K9/22 ,  A61K9/00 ,  A61K31/343

CPC classification number: A61K9/2866 ,  A61K9/2077 ,  A61K9/209 ,  A61K9/284 ,  A61K9/5084 ,  A61K31/137 ,  A61K31/343 ,  A61K31/554 ,  A61K2300/00

Abstract: The present invention relates to a pharmaceutical composition comprising a tablet core comprising a combination of actives selected from the group consisting of bupropion hydrochloride and escitalopram oxalate, bupropion hydrobromide and citalopram hydrochloride, bupropion hydrobromide and escitalopram oxalate, and bupropion hydrobromide and quetiapine fumarate, and at least one pharmaceutically acceptable excipient, and a control-releasing coat surrounding the tablet core, wherein said composition surprisingly provides for a synchronous release of the combination of active agents across in-vitro. The once-daily pharmaceutical composition surprisingly also provides for enhanced absorption of bupropion hydrobromide when administered to a subject in need of such administration.

Abstract translation: 本发明涉及一种药物组合物，其包含片芯，其包含选自盐酸安非他酮和草酸依托普兰，安非他酮氢溴酸盐和盐酸西酞普兰，安非他酮氢溴酸盐和草酸依托普兰以及安非他酮氢溴酸盐和富马酸喹硫平的活性物质的组合， 至少一种药学上可接受的赋形剂和围绕片芯的对照释放包衣，其中所述组合物令人惊奇地提供活体剂的组合在体外的同步释放。 每天一次的药物组合物令人惊奇地还提供了当给予需要这种给药的受试者时，加强安非他酮氢溴酸盐的吸收。

公开(公告)号：US20110052684A1

公开(公告)日：2011-03-03

申请号：US12864453

申请日：2009-01-28

Applicant: Edwin Walsh ,  Graham Jackson ,  Werner Oberegger ,  Xiaopin Jin

Inventor： Edwin Walsh ,  Graham Jackson ,  Werner Oberegger ,  Xiaopin Jin

IPC: A61K31/343 ,  A61K9/22 ,  A61K9/00 ,  A61P25/24 ,  A61P25/22

CPC classification number: A61K9/2866 ,  A61K9/2077 ,  A61K9/209 ,  A61K9/284 ,  A61K9/5084 ,  A61K31/137 ,  A61K31/343 ,  A61K31/554 ,  A61K2300/00

Abstract: The present invention relates to a pharmaceutical composition comprising a tablet core comprising a combination of actives selected from the group consisting of bupropion hydrochloride and escitalopram oxalate, bupropion hydrobromide and citalopram hydrochloride, bupropion hydrobromide and escitalopram oxalate, and bupropion hydrobromide and quetiapine fu-marate, and at least one pharmaceutically acceptable excipient, and a control-releasing coat surrounding the tablet core, wherein said composition surprisingly provides for a synchronous release of the combination of active agents in-vitro. The once-daily pharmaceutical composition surprisingly also provides for enhanced absorption of bupropion hydrobromide when administered to a subject in need of such administration.

Abstract translation: 本发明涉及一种药物组合物，其包含片芯，其包含选自盐酸安非他酮和草酸依托普兰，安非他酮氢溴酸盐和西酞普兰盐酸盐，安非他酮氢溴酸盐和草酸依托普兰以及安非他酮氢溴酸盐和喹硫平， 和至少一种药学上可接受的赋形剂和围绕片芯的对照释放包衣，其中所述组合物令人惊奇地提供了体外活性剂组合的同步释放。 每天一次的药物组合物令人惊奇地还提供了当给予需要这种给药的受试者时，加强安非他酮氢溴酸盐的吸收。

公开(公告)号：US6031749A

公开(公告)日：2000-02-29

申请号：US283141

申请日：1999-03-31

Applicant: John Henry Covington ,  Thomas Edwin Walsh ,  John Mark Newell

Inventor： John Henry Covington ,  Thomas Edwin Walsh ,  John Mark Newell

IPC: H05B41/282 ,  G05F1/10 ,  H02M5/458 ,  H02M7/12 ,  H02M7/217 ,  H05B37/02

CPC classification number: H02M7/2176 ,  H02M5/458 ,  H05B37/02

Abstract: A switch-mode power converter uses a digital signal processor (DSP) to control operation of power semiconductors through gate drive amplifiers, further using the DSP's internal analog-to-digital converters to measure necessary currents, voltages and timings within the main power circuit. Using values captured by the A-to-D converters, software controlling the DSP manipulates duty cycle and timing parameters of the main semiconductor switches to provide at least three different modes of operation for serving a wide range of lighting loads. This power system reduces the size, cost, and weight, of circuitry needed to operate stage lighting equipment. The DSP's microprocessor eliminates most of the complex and dedicated analog circuitry commonly used for electronic power conversion, and a common power circuit topology provides an identical hardware platform for each luminaire circuit. Overall reliability is enhanced because of the reduction in circuit complexity.

Abstract translation: 开关模式电源转换器使用数字信号处理器（DSP）通过栅极驱动放大器来控制功率半导体的操作，进一步使用DSP的内部模数转换器来测量主电源电路内的必要电流，电压和时序。 使用由A到D转换器捕获的数值，控制DSP的软件操纵主半导体开关的占空比和定时参数，以提供至少三种不同的操作模式，用于服务各种各样的照明负载。 该电力系统降低了操作舞台照明设备所需的电路的尺寸，成本和重量。 DSP的微处理器消除了通常用于电子功率转换的大多数复杂和专用的模拟电路，并且通用电源电路拓扑为每个灯具电路提供了相同的硬件平台。 由于电路复杂性的降低，总体可靠性得到提高。